m+Medelevator.RU
← Поиск публикаций
Journal of clinical pathology · 2021

Development of a qualitative real-time RT-PCR assay for the detection of SARS-CoV-2: a guide and case study in setting up an emergency-use, laboratory-developed molecular microbiological assay.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Anahtar Melis N, Shaw Bennett M, Slater Damien, Byrne Elizabeth H, Botti-Lodovico Yolanda, Adams Gordon, Schaffner Stephen F, Eversley Jacqueline, McGrath Graham E G, Gogakos Tasos, Lennerz Jochen, Marble Hetal Desai, Ritterhouse Lauren L, Batten Julie M, Georgantas N Zeke, Pellerin Rebecca, Signorelli Sylvia, Thierauf Julia, Kemball Molly, Happi Christian, Grant Donald S, Ndiaye Daouda, Siddle Katherine J, Mehta Samar B, Harris Jason B, Ryan Edward T, Pierce Virginia M, LaRocque Regina C, Lemieux Jacob E, Sabeti Pardis C, Rosenberg Eric S, Branda John A, Turbett Sarah E

Аннотация

Developing and deploying new diagnostic tests are difficult, but the need to do so in response to a rapidly emerging pandemic such as COVID-19 is crucially important. During a pandemic, laboratories play a key role in helping healthcare providers and public health authorities detect active infection, a task most commonly achieved using nucleic acid-based assays. While the landscape of diagnostics is rapidly evolving, PCR remains the gold-standard of nucleic acid-based diagnostic assays, in part due to its reliability, flexibility and wide deployment. To address a critical local shortage of testing capacity persisting during the COVID-19 outbreak, our hospital set up a molecular-based laboratory developed test (LDT) to accurately and safely diagnose SARS-CoV-2. We describe here the process of developing an emergency-use LDT, in the hope that our experience will be useful to other laboratories in future outbreaks and will help to lower barriers to establishing fast and accurate diagnostic testing in crisis conditions.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты